News

Acadia Pharmaceuticals, a developer of small molecule drugs for the treatment of central nervous system disorders, has reported a net loss of $14m, or $0.38 per share, for

Vivus, a biopharmaceutical company, has reported a net loss of $6.7m, or $0.10 per diluted share, for the fourth quarter of 2008, compared to a net income of

Interleukin Genetics, a genetics-focused personalized health company, has reported a net loss of $1.47m, or $0.05 per share, for the fourth quarter of 2008, compared to a net

This 12-week, randomized, double-blind, placebo-controlled, parallel group comparative study will evaluate the safety and efficacy of Avastrem in the treatment of tardive dyskinesia (TD). The primary objective of

Lipoxen, a biopharmaceutical company, has announced positive results from its completed Phase I trial of SuliXen, its long-acting insulin candidate for type 1 and type 2 diabetes. The

In addition to chronic angina, the Genesis neurostimulation system is approved for treating chronic neuropathic pain of the trunk and limbs and pain from back surgeries that have

Ms Harrison has previously held the position of CFO for the company and takes over for Jonathan Green, CG Therapeutics’s first CEO, in an effort to move the

With the CE mark indicating conformity to European standards for medical devices, both adult and neonatal ThyroChek tests are available for sale worldwide. Screening Devices (SD) Canada is

Under the terms of the agreement, the parties have agreed as the full settlement an amount of C$2 million that was paid to Akela on closing by Lab